The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.
Farhad Ravandi
Consultant or Advisory Role - Sunesis Pharmaceuticals (U)
Honoraria - Sunesis Pharmaceuticals
Research Funding - Sunesis Pharmaceuticals
Ellen K. Ritchie
Consultant or Advisory Role - Sunesis Pharmaceuticals (U)
Honoraria - Sunesis Pharmaceuticals
Hamid Sayar
Consultant or Advisory Role - Sunesis Pharmaceuticals
Honoraria - Sunesis Pharmaceuticals
Stephen Anthony Strickland
No relevant relationships to disclose
Michael Craig
No relevant relationships to disclose
Dominik L. D. Selleslag
No relevant relationships to disclose
Johan Maertens
No relevant relationships to disclose
Violaine Havelange
No relevant relationships to disclose
Jeffrey E. Lancet
No relevant relationships to disclose
Steven B Ketchum
Employment or Leadership Position - Sunesis Pharmaceuticals
Stock Ownership - Sunesis Pharmaceuticals
Gary Acton
Consultant or Advisory Role - Sunesis Pharmaceuticals
Cyrus R. Mehta
Consultant or Advisory Role - Sunesis Pharmaceuticals
Eric Silva
Consultant or Advisory Role - Sunesis Pharmaceuticals
Adam Craig
Employment or Leadership Position - Sunesis Pharmaceuticals
Judith Ann Fox
Employment or Leadership Position - Sunesis Pharmaceuticals
Stock Ownership - Sunesis Pharmaceuticals
Robert K. Stuart
Consultant or Advisory Role - Sunesis Pharmaceuticals (U)
Honoraria - Sunesis Pharmaceuticals
Research Funding - Sunesis Pharmaceuticals
Expert Testimony - Sunesis Pharmaceuticals (U)
Harry Paul Erba
Consultant or Advisory Role - Sunesis Pharmaceuticals (U)
Honoraria - Celgene; Novartis
Research Funding - Ambit BioSciences; Ascenta Therapeutics; Chroma Therapeutics; Genzyme; Lilly; Millennium; Novartis; Sanofi
Norbert Vey
Consultant or Advisory Role - Sunesis Pharmaceuticals (U)
Honoraria - Sunesis Pharmaceuticals
Gary J. Schiller
Consultant or Advisory Role - Sunesis Pharmaceuticals (U)
Honoraria - Sunesis Pharmaceuticals
Eric Jay Feldman
Consultant or Advisory Role - Sunesis Pharmaceuticals (U)
Honoraria - Sunesis Pharmaceuticals